NVCA is closely monitoring the outbreak of the coronavirus (COVID-19) and is working diligently to address the VC industry’s needs and provide resources that aim to help firms and portfolio companies during this challenging time.
READ MORE
“NVCA plays a vital role in America’s entrepreneurial economy. We are strong believers in need for a voice, both in D.C. and nationally, regarding favorable tax, immigration, patent reform, capital formation, pro-risk capital regulation, etc. Since joining the Association, we’ve also been pleased to focus on regional investing.” – Will Price, Next Frontier Capital
READ MORE
“NVCA does important work to elevate the VC ecosystem and industry as a whole. It’s a great advocate and influential voice around public policy for our industry and a great resource for a firm like High Alpha. In addition, resources and research that NVCA produces are extremely valuable.” – Blake Koriath, High Alpha
READ MORE
READ MORE
“NVCA plays an important national role in highlighting venture capital as one of the primary growth engines for the US economy. These efforts ensure fair regulatory treatment of startups and VCs, and we are grateful for them.” – Guy Turner, Hyde Park Venture Partners
READ MORE
READ MORE
NVCA unites the U.S. venture ecosystem to support the formation of high-growth companies and ensure the U.S. remains the most competitive environment in the world for entrepreneurs.
NVCA is a nonprofit association powered by our members. We convene venture capital investors, entrepreneurs, and industry partners to shape public policy priorities, to develop new industry initiatives, to provide premier research, and to participate in professional development opportunities with their peers.
Creating the Next Moderna: What VC Offers the World and 3 Public Policy Lessons
blog, Public Policy /by Jeff FarrahThe world has anxiously waited for encouraging news about COVID-19 vaccine candidates. Happily, this news came right before Thanksgiving, with Moderna reporting that its vaccine is more than 94% effective and Pfizer indicating that its vaccine was similarly effective.